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Ischemic vascular diseases include different pathological
events characterized by distinctive features but share the
common hallmark of inflammation. In this light, myocardial
infarction can be a good paradigm to summarize the different
connections linking inflammation and the cardiovascular
system during an ischemic event. The immune system and
inflammation, through several cellular and soluble in-
flammatory mediators, play a crucial role in the local tissue
structural changes of ischemic heart disease, with a different
impact and outcome during acute myocardial infarction
compared to the more chronic long-term inflammation [1].
In response to acute damage and hemodynamic stress, there
is expansion of resident immune cells and recruitment of
extra cells involved in a critical cross talk with parenchymal
cells [2, 3]. In other words, postischemic tissue repair is
crucial to survival. Recruited inflammatory cells can remove
debris and facilitate the repair process; conversely, unre-
strained inflammation inhibits optimal healing leading to
adverse events. Moreover, other mediators such as some
key coagulation factors might influence innate immunity as
well as cell-mediated reactions like healing, response to tissue
injury, or inflammatory processes [4, 5]. Overall, as recently
suggested, the different immune/inflammatory cell subsets
act as messengers implicated in novel inflammatory networks
that link different organ systems enlarging the continuum
beyond the myocardium and blood vessels in a more integra-
tive pathophysiology standpoint [6].
This special issue aims to collect insights about this cross
talk with a dual purpose: on the one hand to expand the
comprehension on the mechanisms of action and impact of
“old” inflammatory mediators and on the other to bring
out “new” potential pathways and intermediates. The overall
aim is to increase knowledge on the pathophysiological
processes of ischemic vascular disease to improve diagnosis
and treatment.
The first set of articles draws attention to soluble and
cellular circulating mediators with a role in vascular in-
flammation. M. L. Morieri et al. have considered an “old”
inflammatory factor such as interleukin 6 (IL-6) that shows
different effects on the acute inflammatory responses com-
pared with that of chronic low-grade systemic inflammation.
In particular, since the “transsignalling” mediated by IL-6 is
more linked to the harmful actions of this cytokine especially
in the cardiovascular setting, the specific targeting of this
pathway by using inhibitors such as soluble glycoprotein
130 might be a promising therapeutic strategy. The article
of B. Toffoli et al. addresses the role of two other cytokines
belonging to the TNF family. Osteoprotegerin (OPG) and
TNF-related apoptosis-inducing ligand (TRAIL) are two
factors showing controversial effects on several physiopatho-
logical contexts [7, 8]. In a preclinical model, the authors
show that dyslipidaemia and diabetes, two risk factors for
cardiovascular disease, modify the vascular and cardiac
expression of OPG and TRAIL leading to an increased
OPG/TRAIL ratio. This alteration could contribute to the
changes in circulating OPG/TRAIL ratio observed in patients
with diabetes and cardiovascular disease, and they could
mediate/contribute to atherosclerosis development and car-
diac remodelling. As far as cellular mediators, H. Li et al.
have addressed the role of neutrophil granulocytes in the
pathophysiology of vascular disease in a wide cohort of
patients undergoing chronic haemodialysis. In the same line,
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R. Helseth et al. deal with neutrophil cell activation in acute
myocardial infarction. The profile and role of neutrophil
extracellular traps (NET), namely, spindle-like networks
made in the extracellular space by neutrophil, have been
addressed in patients with ST-elevationmyocardial infarction
suggesting a role of NET in acute and chronic athero-
thrombosis in line with previous studies [9, 10]. Finally, W.
Zhong et al. have amethodological and “laboratory-oriented”
approach and propose an experimental method to evaluate
the role of CD137 (41-BB) signalling in the pathogenesis of
the atherosclerotic plaque and vascular damage.
Other authors have indeed contributed to the main topic
of the special issue by exploring possible mechanisms under-
lying the pathophysiology of ischemic diseases. S. Wang et al.
and M. Neri et al. address ischemia reperfusion injury, one of
the Achilles heels of the current therapy for ischemic vascular
diseases. In their work, S. Wang et al. highlight autophagy as
a fundamental mechanism involved in ischemic pathology in
an experimental model of diabetes. In the same line but from
a different perspective, M. Neri et al. review the current
literature on the ischemia reperfusion injury following
myocardial infarction, highlighting the relevance of a calpain
system, oxidative and NO-linked pathways, and ventricular
remodelling discussing the evidences from a medico-legal
standpoint to better understand sudden deaths following
myocardial infarction [11, 12]. Finally, M. V. Arcidiacono
et al. change perspective and address the cross talk between
cardiovascular and kidney systems showing that patients
with chronic kidney disease are prone to develop cardio-
vascular events in a mutual relationship. Indeed, they dem-
onstrate that the higher incidence of microangiopathy of
the common carotid artery wall drives the higher incidence
of atheromatous disease in these patients.
In conclusion, we are pleased to introduce the reader to
this translational research topic on inflammation and vascu-
lar cross talk in ischemic diseases. We hope that the research
articles/reviews selected and presented might be an opportu-
nity for further discussions and future deeper investigations
to move forward by improving knowledge in the field, with
the overall aim of increasing the available diagnostic and
therapeutic options in the context of ischemic diseases.
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